Impact of Ageing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Impact of Ageing
Despite the fact that Europe's population is ageing rapidly, the region is astonishingly still underprepared for dealing with the health-related effect of this demographic trend. A major challenge for governments in the EU is meeting rising demand for healthcare whilst tailoring the systems to needs of the elderly.

Pharmaceutical Technology Europe
Volume 23, Issue 12


Europe faces serious challenges in sustaining its healthcare systems to deliver high quality services to the elderly. Initiatives are being launched at a European level and have received high profile backing from the EC, the EMA and key geriatricians. Such an approach has led to improvements in addressing the gaps seen in paediatric medicine and is seen as a potential model for making improvements with respect to the elderly. Sadly, the ongoing economic difficulties in Europe may hinder investment in additional healthcare services for the elderly as politicians look to implement cutbacks. However, the elderly also represent a growing proportion of the voting population and will therefore not accept their long-term healthcare needs being ignored. For the pharmaceutical industry the demographic trends present opportunities to launch new therapies in these disease areas.


1. EC, "Elderly" (2011)., accessed Nov. 11, 2011.

2. D.M. Qato et al., J. Gerontol. B. Psychol. Sci. Soc. Sci. 64 Suppl. 1, i86–93 (2009).

3. P.A. Rochon et al., "Drug prescribing for older adults," UpToDate (2011)., accessed Nov. 11, 2011.

4. EC, "European Innovation Partnership agrees on actions to turn ageing into an opportunity," Press Release (2011)., accessed Nov. 11, 2011.

5. BBC News, "Eurozone's growth has stalled, says EU," (2011)., accessed Nov. 11, 2011.

6. PREDICT, "Increasing the participation of the elderly in clinical trials," (2011)., accessed Nov. 11, 2011.

7. A. Cherubini, Arch Intern Med. 171(6), 550–556 (2011).

8. EMA, "EMA workshop on medicines for older people," (2011)., accessed Nov. 11, 2011.

9. Decision Resources, "The Alzheimer's disease drug market will nearly triple over the next ten years," (2011)., accessed Nov. 11, 2011.

10. A. Palmer, "It's not Nice… but the alternative is worse." (Daily Telegraph, 2007)., accessed Nov. 11, 2011.

11. Inpharm, "Pfizer has signed a five-year research pact with US healthcare insurer Humana," (2011)., accessed Nov. 11, 2011.

12. G. Forrer, "Treating chronic disease could help forestall onset of Alzheimer's disease," (PhRMA, 2011)., accessed Nov. 11, 2011.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology Europe,
Click here